AXL and melanoma: To determine whether molecular markers of differentiation state, MAPK activity, or other phenotypic markers could predict the differential efficacy of epigenetic treatments, we measured both baseline levels and treatment-induced variations in Mitf, Ngfr, Axl, Sox10, p-ErkT202/Y204, p-S6S235/S236, and Ki67 across eight melanoma cell lines.